stockrow
Friday 6 November 2026
Export DNLI’s income statement to Excel — free account
Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
20.12
0.40
+2.03%
Follow DNLI
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 16.11 | 171.93 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (49.67) | (33.16) | |
P/B ratio |
— | — | 5.77 | 4.20 | |
Price to Tangible BV |
— | — | 6.02 | 4.37 | |
EV/Sales |
— | — | 13.76 | 149.38 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (9.48) | (7.62) | |
EV/FCF |
— | — | (9.40) | (7.52) | |
Quick Ratio |
8.82 | 8.97 | 7.93 | 5.62 | |
Current Ratio |
9.16 | 9.28 | 8.37 | 6.21 | |
Net Debt/EBITDA |
6.33 | 7.23 | 5.49 | 4.11 | |
Debt/Assets |
0.48% | 0.44% | 0.47% | 0.43% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.26 | 0.02 | |
Operating CF/Net income |
0.77 | 1.02 | 0.76 | (1.67) | |
Capex/Depreciation |
(1.25) | (1.55) | (0.38) | (0.39) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 2,691.98% | 596.82% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 1,006.74% | 210.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 635.82% | 128.58% | |
Graham Net Nets |
— | — | 0.09 | 0.07 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (11.04%) | (8.36%) | |
Free Cash Flow Yield |
— | — | (9.08%) | (11.56%) | |
Revenue per Share |
0.00 | 0.00 | 0.02 | 0.09 | |
Operating CF per Share |
(0.57) | (0.70) | (0.52) | (0.62) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.58) | (0.72) | (0.52) | (0.63) | |
Cash per Share |
5.03 | 5.29 | 3.79 | 2.74 | |
Shareholders Equity per Share |
5.87 | 4.96 | 4.46 | 4.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.87 | 4.96 | 4.46 | 4.92 | |
Free Cash Flow |
(100.06) | (133.67) | (97.81) | (118.45) | |
Working Capital |
802.31 | 912.60 | 663.84 | 496.45 | |
Capital Expenditures |
(1.52) | (2.47) | (0.80) | (1.01) | |
Net Current Asset Value |
769.57 | 682.83 | 431.15 | 262.06 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.22 | 0.06 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 1.96 | 11.94 | |
Average Payables |
5.82 | 24.42 | 11.33 | 10.22 | |
Average Assets |
1,259.52 | 1,268.68 | 1,162.10 | 1,155.83 | |
Average Common Equity |
1,121.72 | 1,024.39 | 931.12 | 926.29 |
Columns are period end dates · fundamentals updated 5 Nov 2026